Advertisement

Benzodiazepines and Other Sedatives, Hypnotics, and Anxiolytics

  • Christine LaGrotta
  • Anil Thomas
Chapter
  • 64 Downloads

Abstract

The sedative, hypnotic, and anxiolytic class of medication includes benzodiazepines, barbiturates, and the nonbenzodiazepine “Z-drugs.” Tolerance, dependence, and withdrawal can occur with any of these medications when misused or used for treatment. Benzodiazepines are of concern with their use contributing to opioid overdoses. It is important to recognize and treat, as well as prevent, sedative, hypnotic, and anxiolytic use disorders. Cessation, especially abrupt withdrawal, of any of these medications can lead to a clinically significant withdrawal syndrome, which must be immediately recognized by providers and treated as a medical emergency. Benzodiazepines, barbiturates, and the nonbenzodiazepine “Z-drugs” have distinct, though variably overlapping, clinical manifestations of intoxication and withdrawal, which are described. Treatment of sedative-hypnotic use disorders, including pharmacological, therapeutic, and psychosocial, will be covered elsewhere in this book.

Keywords

Benzodiazepine Barbiturate Z-drug Sedatives Treatment Withdrawal GABA Tolerance 

References

  1. 1.
    McCance-Katz EF. The national survey on drug use and health. Substance Abuse and Mental Health Services Administration. 2017. https://www.samhsa.gov/data/sites/default/files/nsduh-ppt-09-2018.pdf.
  2. 2.
    Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013. Am J Public Health. 2016;106(4):686–8.CrossRefGoogle Scholar
  3. 3.
    Blanco C, Han B, Jones CM, Johnson K, Compton WM. Prevalence and correlates of benzodiazepine use, misuse, and use disorders among adults in the United States. J Clin Psychiatry. 2018;79(6)Google Scholar
  4. 4.
    Drugabuse.gov. Overdose Death Rates. [online]. 2019. Available at: https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates. Accessed 9 May 2019.
  5. 5.
    McHugh RK, Votaw VR, Bogunovic O, Karakula SL, Griffin ML, Weiss RD. Anxiety sensitivity and nonmedical benzodiazepine use among adults with opioid use disorder. Addict Behav. 2017;65:283–8.CrossRefGoogle Scholar
  6. 6.
    Kan CC, Hilberink SR, Breteler MH. Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach. Compr Psychiatry. 2004;45(2):88–94.CrossRefGoogle Scholar
  7. 7.
    Griffin CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system–mediated effects. Ochsner J. 2013;13(2):214–23.PubMedPubMedCentralGoogle Scholar
  8. 8.
  9. 9.
    Vhpharmsci.com. Comparison of Benzodiazepines. [online]. 2019. Available at: http://www.vhpharmsci.com/vhformulary/tools/benzodiazepines-comparison.htm. Accessed 10 May 2019.
  10. 10.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). Arlington, VA: American Psychiatric Publishing; 2013 May 22.Google Scholar
  11. 11.
    Gaudreault P, Guay J, Thivierge RL, Verdy I. Benzodiazepine poisoning. Drug Saf. 1991;6(4):247–65.CrossRefGoogle Scholar
  12. 12.
    Nasky KM, Cowan GL, Knittel DR. False-positive urine screening for benzodiazepines: an association with sertraline?: a two-year retrospective chart analysis. Psychiatry (Edgmont). 2009;6(7):36.Google Scholar
  13. 13.
    Weinbroum AA, Flaishon R, Sorkine P, Szold O, Rudick V. A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose. Drug Saf. 1997;17(3):181–96.CrossRefGoogle Scholar
  14. 14.
    Schöpf J. Withdrawal phenomena after long-term administration of benzodiazepines a review of recent investigations. Pharmacopsychiatry. 1983;16(01):1–8.CrossRefGoogle Scholar
  15. 15.
    Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev. 2006;3Google Scholar
  16. 16.
    Sadock BJ, Sadock VA. Kaplan and Sadock’s synopsis of psychiatry: behavioral sciences/clinical psychiatry: Philadelphia, PA: Lippincott Williams & Wilkins; 2015.Google Scholar
  17. 17.
    Sivilotti ML. Flumazenil, naloxone and the ‘coma cocktail’. Br J Clin Pharmacol. 2016;81(3):428–36.CrossRefGoogle Scholar
  18. 18.
    Gunja N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol. 2013;9(2):155–62.CrossRefGoogle Scholar
  19. 19.
    Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Clin Pharmacokinet. 1995;29(3):142–53.CrossRefGoogle Scholar
  20. 20.
    Brielmaier BD. Eszopiclone (Lunesta): a new nonbenzodiazepine hypnotic agent. In Baylor University Medical Center Proceedings 2006 Jan 1 (vol. 19, no. 1, pp. 54–59). Taylor & Francis.Google Scholar
  21. 21.
    Dooley M, Plosker GL. Zaleplon. Drugs. 2000;60(2):413–45.CrossRefGoogle Scholar
  22. 22.
    Sankar R. GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs. 2012;26(3):229–44.  https://doi.org/10.2165/11599020.CrossRefPubMedGoogle Scholar
  23. 23.
    Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of γ-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol. 1989;25(3):213–20.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Christine LaGrotta
    • 1
  • Anil Thomas
    • 1
  1. 1.Department of PsychiatryIcahn School of Medicine at Mount Sinai, Mount Sinai St. Luke’s-WestNew YorkUSA

Personalised recommendations